A new study by researchers from the University of Pennsylvania’s Perelman School of Medicine, Yale School of Medicine, and UT Southwestern Medical Center suggests that GLP-1 drugs, commonly used for weight loss, could be personalized to better meet individual patient needs. The study analyzed data from over 13,000 overweight participants using the Cardiometabolic Efficacy Index (CEI), which measures factors such as body weight, waist circumference, blood sugar levels, blood pressure, triglycerides, and cholesterol levels.

Findings showed that higher dosages of GLP-1 agonists generally led to greater cardiometabolic improvements. Specifically, semaglutide injections at 7.2 mg achieved the highest CEI, outperforming 36 mg of orforglipron and 2.4 mg of injected semaglutide. All treatments delivered placebo-adjusted weight reductions of at least 10 percent of participants’ body weight on average.

Senior author Yong Chen, PhD, a professor of Biostatistics at Penn, emphasized the importance of a tailored approach: “We hope that clinicians are encouraged by this study to take a more comprehensive and individual approach to treatment selection.” Chen added, “For patients, the key message is that there may not be a single ‘best’ GLP-1 therapy for everyone, and it all could really depend on what their individual goals and needs are.”

The research, published in "Diabetes, Obesity, and Metabolism," highlights the potential for GLP-1 drugs to have a broader impact beyond obesity treatment alone.

Sources